Identification of Hepatic Lesions - Full Text View

Sponsored by:	Bayer
Information provided by:	Bayer
ClinicalTrials.gov Identifier:	NCT00307866

Purpose

Patients with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment.

Condition	Intervention	Phase
Hepatic Neoplasms	Procedure: Resovist	Phase IV

MedlinePlus related topics: Cancer Liver Cancer

Drug Information available for: Ferumoxides

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	A Prospective, Multicenter, Phase III b Clinical Study to Evaluate the Effectiveness of Unenhanced and SH U 555A (Resovist) Enhanced MRI, Compared to Contrast-Enhanced Dual-Phase Spiral CT in Assessing the Correct Final Therapy-Deciding Diagnosis, in Patients With Primary or Secondary Hepatic Malignancies.

Further study details as provided by Bayer:

Primary Outcome Measures:

To assess the proportion of correct final, therapy deciding diagnosis based on unenhanced plus SH U 555 A enhanced MR imaging compared to contrast-enhanced dual-phase spiral CT.

Secondary Outcome Measures:

To assess the number, size , location and character of liver lesions.
To assess the diagnostic confidence of MRI and CT.
To assess the proportion of changed therapeutical decisions
To assess sensitivity and specificity of MRI and CT.
To assess safety and tolerability of SH U 555 A administration.

Study Start Date:

April 2001

Detailed Description:

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Present with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment. There should not be morethan five liver lesions on type visualized on CT.

The patient should be in a condition that allows subsequent treatment.
Be willing and able to continue study participation following administration of SH U 555 A to ensure completion of all procedures and observations required by the trial protocol.
Sign and date fully informed consent prior to entry into the study.

Exclusion Criteria:

Patients under 18 years of age.
Patients weighing less than 35 kg.
Patients who have received any investigational drug within the 30 days prior to entering this study.
Patients who have previously entered this study or any other study performed with SH U 555 A.
Women who are pregnant or who are of childbearing potential and have not had a negative urine pregnancy test immediately prior to the administration of SH U 555 A. The urine pregnancy test should be performed in accordance with the manufacturer’s recommendations.
Lactating women.
Patients who have any contraindication to MRI examination.
Patients who have received any contrast material in the 24 hours prior to SH U 555 A injection, or who are scheduled to receive any contrast material within 24 hours afterwards. (In the case of any liver specific agent (e.g. MnDPDP, SPIOs, Gd-BOPTA) this will be extended to 14 days prior to the study).
Patients who have received Lipiodol contrast material at any time in the past or are scheduled to receive this during the study period.
Patients who are clinically unstable and whose clinical course during the observation period is unpredictable (e.g. due to previous surgery).
Patients scheduled for liver biopsy within 24 hours, or who had a biopsy within the 24 hours prior to planned SH U 555 A injection.
Patients who are scheduled for, or are likely to require, surgery within 24 hours after SH U 555 A injection.
Patients with a history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents.
Patients with known hypersensitivity to any of the ingredients of SH U 555 A.
Patients with already clear op-indication

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00307866

Sponsors and Collaborators

Bayer

Investigators

Study Director:

Bayer Schering Pharma AG, Germany, Medical affairs

phone: +49 30 46811800

More Information

Study ID Numbers:	304668
Study First Received:	March 27, 2006
Last Updated:	April 30, 2007
ClinicalTrials.gov Identifier:	NCT00307866
Health Authority:	Italy: Ministry of Health

Keywords provided by Bayer:

Known or suspected focal liver lesions detected by spiral CT

Study placed in the following topic categories:

Liver Neoplasms
Liver Diseases
Digestive System Diseases
Digestive System Neoplasms

Liver neoplasms
Neoplasm Metastasis
Gastrointestinal Neoplasms

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 14, 2009